Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...

Acquisition builds on UCB’s 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.Lead investigational asset, NRTX-1001, a ...

Neurona Therapeutics develops regenerative cell therapies for epilepsy and other nervous system conditions. Through the ...

The takeover – which, if completed, will be the third acquisition for UCB this decade – involves an upfront payment of $650 ...

Temporal lobe epilepsy, which results in recurring seizures and cognitive dysfunction, is associated with premature aging of brain cells. A new study from researchers at Georgetown University Medical ...

In a retrospective cohort, a clinical heuristic composed of eight binary variables helped identify which patients with medial temporal lobe epilepsy (MTLE) were best suited for stereotactic laser ...

Belgian pharma company UCB (UCBJY) on Friday announced an agreement to acquire Neurona Therapeutics, a U.S.-based developer of cell therapies for neuronal diseases, for a total consideration of up to ...

Seizures can be predicted more than 30 minutes before onset in patients with temporal lobe epilepsy, opening the door to a therapy using electrodes that could be activated to prevent seizures from ...

Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy ...